The Filing Desk

ADMA Biologics vs Tarsus Pharmaceuticals

ADMA Biologics ADMA · Tarsus Pharmaceuticals TARS · Biotechnology

ADMA Biologics reported revenue of $510 million in fiscal 2025, about the same as Tarsus Pharmaceuticals' $451 million in fiscal 2025. ADMA Biologics' revenue grew 19.6% in its latest year, and Tarsus Pharmaceuticals' grew 146.7%. ADMA Biologics had an operating margin of 37.5%, against -15.7% at Tarsus Pharmaceuticals. Free cash flow was $28 million at ADMA Biologics and −$22 million at Tarsus Pharmaceuticals.

Side by side

ADMA BiologicsTarsus Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$510M$451M
Revenue growth19.6%146.7%
Revenue growth a year, last 5 years64.6%—
Gross margin57.4%—
Operating margin37.5%−15.7%
Net margin28.8%−14.7%
Free cash flow$28M−$22M
Free cash flow margin5.5%−4.9%
Return on capital39.5%—
Net debt to EBITDA−0.1x—
Dividends and buybacks$32M$0M
Change in diluted share count0.6%11.1%
Last close$13.68$80.28
P/E at the last close17.8×—
Insider trades, last 12 monthsbought $468,294, sold $3.3 millionsold $20.0 million
Piotroski F-score5 of 94 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ADMA BiologicsTarsus Pharmaceuticals
Operating margin
Percent of revenue
ADMA BiologicsTarsus Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ADMA BiologicsTarsus Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ADMA Biologics and Tarsus Pharmaceuticals pages.